

~~CLAIMS~~
WHAT IS CLAIMED IS:

1. A pharmaceutical composition for stimulation of the immune response of an organism, characterized in that it comprises as the active ingredient MHC molecules extracted from animal or human tissues, serum or cells.
2. A pharmaceutical composition, according to claim 1, for the treatment of cancer pathologies.
3. A pharmaceutical composition, according to claim 1, for the treatment of viral pathologies.
4. A pharmaceutical composition, according to ~~one of the~~ claim 1 ~~previous claims~~, characterized in comprising MHC molecules of different origin, in separate packaging, for successive administration of such molecules.
5. A pharmaceutical composition, according to claim 4, characterized in that such molecules originate from different species. B
6. A pharmaceutical composition, according to ~~one of the~~ claim 1 ~~previous claims~~, characterized in that such MHC molecules are obtained as an extract from animal tissues, cells or sera by the use of detergents and that they have a molecular weight of more than 10,000 daltons.
7. A pharmaceutical composition, according to claim 6, characterized in that such tissues, cells or sera are chosen from goat, veal or pig liver and bovine red blood cells.
8. Histocompatibility molecules for use as a medicament in stimulation of the immune system and cancer therapy.

9. Histocompatibility molecules of different origin, for use in sequential administration as a medicament in cancer therapy and stimulation of the immune system.

Sub
B1

10. The use of histocompatibility molecules, for preparation of a pharmaceutical composition for stimulation of the immune system and treatment of cancer pathologies.

11. Use, according to point 10, in which such histocompatibility molecules are of different origin.

12. A process for the extraction of histocompatibility molecules ~~according to one of the previous points~~, characterized in that it comprises the following steps: homogenizing the original material in the presence of Nonidet P40; centrifuging the homogenate and separating the supernatant; dialyzing the supernatant against PBS through membranes with a cutoff of at least 10 kDa.

13. A process according to claim 12, wherein such homogenization is carried out until cell lysis is substantially complete, and wherein 150 to 450 ml of PBS and 0.3 to 1.8% Nonidet P40 (v/v) are used for each 100 g of original material.

14. A method for stimulation of the immune system of an organism for the treatment of cancer pathologies, characterized in administering to the organism MHC molecules extracted from animal or human tissues, serum or cells.

15. A method according to claim 14, characterized in administering in sequence or alternately histocompatibility molecules of different origin.

16. A method according to claim 15, wherein such histocompatibility molecules are obtained from tissues, cells or sera of different species.

add
B2

add 1